Drug Trial Radar · NCT00152035
Safety of SPD465 in Treating Adults With ADHD.
Last checked: Nov 19, 2026Latest source record: Aug 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
505
Actual
Start
Mar 10, 2005
Primary completion
Nov 7, 2006
Study completion Nov 7, 2006
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 9, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and effectiveness of SPD465 in the treatment of ADHD. The study will also look at how SPD465 affects sleep.
Conditions
- Attention Deficit Disorder With Hyperactivity
Interventions
Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The evaluation of safety will be based on the occurrence of treatment emergent AEs and specific evaluation of vitals signs, ECG, laboratory and physical examination.Time frame: Throughout the study period of approximately 20 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.